Harmony Biosciences Holdings, Inc.

HRMY Nasdaq CIK: 0001802665

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Mailing Address 630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Phone (484) 539-9800
Fiscal Year End 1231
EIN 822279923

Financial Overview

FY2025

$401.41M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 14, 2026 View on SEC
4 Insider stock transaction report April 9, 2026 View on SEC
3 Initial insider ownership report April 6, 2026 View on SEC
4 Insider stock transaction report April 6, 2026 View on SEC
4 Insider stock transaction report April 6, 2026 View on SEC
DEF 14A Definitive proxy statement April 3, 2026 View on SEC
8-K Current report of material events April 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
10-K Annual financial report February 24, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC

Material Events

8-K Leadership Change April 14, 2026
High Impact
  • Appointment of Glenn Reicin as CFO, signaling a strategic shift toward capital deployment and growth.
  • Reiteration of strong 2026 revenue guidance of $1.0B to $1.04B.
View Analysis
8-K Leadership Change April 2, 2026
High Impact
  • Strategic leadership overhaul to transition from single-product to mature pharma player
  • Appointment of Peter Anastasiou as COO to drive operational execution
View Analysis

Insider Trading

STRONG SELL 2 insiders 6 recent transactions
View Insider Trading Dashboard

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.